Company · Private
Cambrian Biopharma
Holding company building a portfolio of programmes against established aging pathways, including AMPK activation, mTORC1-selective inhibition, TG2 inhibition and AMH/AMHR2 biology.
Listing
Private
Ticker
—
Headquarters
—
Founded
—
Technology
Portfolio model across aging pathways
Category
Longevity thesis
A portfolio structure spreads the binary risk of aging biology across several validated mechanisms while sharing development infrastructure.
Programmes
- AMPK activatorPreclinical
Metabolic aging
- mTORC1-selective inhibitorPreclinical
Nutrient sensing
- TG2 inhibitorPreclinical
Fibrosis and tissue aging
- AMH/AMHR2 programmePreclinical
Reproductive aging
Reference information for research context only. It is not a rating, a valuation or investment advice. Published developments appear in the News archive.